Akèy › Leksemi mieloïd egi › North Carolina › Winston-Salem
Etid klinik pou Leksemi mieloïd egi nan Winston-Salem, NC
18 etid pou Leksemi mieloïd egi ap chèche patisipan nan sit nan ak bò kote Winston-Salem (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Ap rekriteFaz 2
- Novant Health Forsyth Medical Center, Winston-Salem
- Wake Forest University Health Sciences, Winston-Salem
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Ap rekriteFaz 1
- Wake Forest University Health Sciences, Winston-Salem
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Novant Health Forsyth Medical Center, Winston-Salem
- Wake Forest University Health Sciences, Winston-Salem
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Ap rekriteFaz 3
- Novant Health Winston Salem, Winston-Salem
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Wake Forest University Health Sciences, Winston-Salem
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Wake Forest University Health Sciences, Winston-Salem
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Wake Forest University Health Sciences, Winston-Salem
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Ap rekriteFaz 3
- Wake Forest University Health Sciences, Winston-Salem
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
Ap rekriteFaz 2
- Atrium Health Wake Forest Baptist Medical Center, Winston-Salem
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Ap rekriteFaz 1/2
- Wake Forest University Health Sciences, Winston-Salem
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
Ap rekriteFaz 1
- Wake Forest University Health Sciences, Winston-Salem
Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
Ap rekriteEtid obsèvasyon
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia
Ap rekrite
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
Ap rekriteFaz 2
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
Ap rekrite
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Section of Hematology/Oncology, Winston-Salem
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
Ap rekriteEtid obsèvasyon
- Wake Forest Baptist Health, Winston-Salem
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Ap rekriteFaz 1/2
- Atrium Wake Forest Baptist Medical Center, Winston-Salem
Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
Ap rekriteFaz 1/2
- Novant Health Cancer Institute, Winston-Salem
Etid Leksemi mieloïd egi nan lòt vil
- Houston, TX85 etid
- New York City, NY51 etid
- Boston, MA44 etid
- Seattle, WA41 etid
- Baldwin Park, CA40 etid
- Columbus, OH35 etid
- Philadelphia, PA34 etid
- Durham, NC33 etid
- Atlanta, GA31 etid
- Tampa, FL29 etid
- Chicago, IL26 etid
- Portland, OR25 etid
Lòt etid nan Winston-Salem
- Kansè (tout kalite)19 etid
- Myelom Miltip14 etid
- Kansè nan tete14 etid
- Maladi kadyovaskilè14 etid
- Kansè Poumon ki pa ti selil12 etid
- BPCO10 etid
- Kansè ovè10 etid
- Dyabèt Tip 29 etid
- Sendwòm myelodisplastik9 etid
- Gliyoblastòm8 etid
- Lukemi lenfositè kwonik8 etid
- Kansè poumon8 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.